01:24 PM EDT, 06/20/2025 (MT Newswires) -- Argenx (ARGX) said Friday its Vyvgart injectable monotherapy for the treatment of chronic inflammatory demyelinating polyneuropathy in adult patients has received European Commission approval.

The Commission's approval of the neuromuscular disorder treatment is founded on a positive recommendation from the Committee for Medicinal Products for Human Use and encouraging trial results, the company said.

The Adhere trial showed 66.5% of the 322 participants demonstrated evidence of clinical improvement and reached its primary endpoint of a 61% drop in risk of relapse, the company said.

The regulatory approval is the second for Vyvgart in Europe, it added.

Shares of the company were up 1.2% in recent trading.

Price: 544.17, Change: +6.25, Percent Change: +1.16